Persistent aplasia is a rarely reported complication after intensive chemotherapy for AML and is associated with high morbidity and mortality. A small number of reports have treated persistent aplasia after chemotherapy for AML with allogeneic haematopoietic SCT (HSCT). 1 In the current report, we describe a case of invasive fungal infection (IFI) necessitating simultaneous pneumonectomy and allogeneic HSCT as a result of severe iatrogenic aplasia.
In October 2006, we diagnosed a 24-year-old female with AML, not otherwise specified with trisomy 8. Induction was instituted in accordance with the Australasian Leukaemia and Lymphoma Group M12 Trial that compared two schedules of consolidation therapy in a prospective randomised fashion that consisted of idarubicin, etoposide and cytosine arabinoside. Induction chemotherapy was well tolerated, and haematological (specifically neutrophil) recovery was achieved by day 28. BM biopsy on day 39 revealed complete morphological and cytogenetic response. She was randomised to the idarubicin dose escalation arm and received Peg G-CSF on day 8 of her consolidation. Haematological recovery was delayed, and BM examination on day 57 revealed severe hypoplasia, without evidence of residual AML. The patient remained pancytopenic for 85 days after consolidation despite G-CSF treatment and was red blood cell and platelet transfusion dependent. During this period, she experienced episodes of febrile neutropenic sepsis and persistent bacteremia with Escherichia coli and multiresistant coagulase negative staphylococcus. These were treated with meropenem and teicoplanin, respectively. On day 46 despite itraconazole prophylaxis, peripheral nodular lesions were detected on high-resolution computed tomography scan of her chest (Figure 1a) . Voriconazole was started as treatment for possible invasive aspergillosis, but she developed progressive high-resolution computed tomography changes, increasing respiratory failure and required ventilatory support on day 74. As a result, a number of changes were made to antimicrobial therapy including the addition of tigecycline, gentamicin, liposomal amphotericin B and caspofungin. A lung biopsy performed on day 76 revealed intra-alveolar haemorrhage, with no fungal elements seen on Gomori methenamin silver stain. Serum Aspergillus galactomannan was strongly positive. As a result of increasingly deranged liver function tests, caspofungin was ceased and posaconazole via nasogastric tube together with feeds was commenced. The left upper lobe nodule progressed to a 5 Â 7 Â 6 cm lesion despite treatment with liposomal amphotericin B and posaconazole (Figure 1b) . A computed tomography (CT)-guided lung biopsy was performed on day 84 of the left upper lobe lesion that revealed broad-based, ribbon-like, non-septate hyphae suggestive of Mucor (Figure 2) .
The patient had progressive IFI. Simultaneous nonmyeloablative haematopoietic HSCT and left pneumonectomy were proposed as salvage therapy. The almost certain mortality that would have ensued with the use of systemic immunosuppression for treatment of GVHD lead to the decision to proceed with a highly T-cell-depleted graft. A fully matched sibling (HLA-A, -B, -C, -DR and -DQ) was available. On day 81, conditioning with fludarabine (30 mg/ m 2 (three doses)) and antithymocyte globulin (30 mg/kg (five doses)) was commenced, followed by infusion of G-CSF-mobilised T-cell-depleted PBSCs (in vitro CD34 þ selection/T-cell depletion using CliniMACS system, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) on day 85. The dose of CD34 þ stem cells infused was 7.22 Â 10 6 / kg. On day 88, a left pneumonectomy was performed. The patient was transplanted on a ventilator and extubated after the pneumonectomy. Given that neutrophil engraftment and avoidance of further immunosuppression were critical to control the progressive infection, and the knowledge that CD3 þ depletion achieved by magnetic separation is 495% along with lymphocytotoxic concentrations of antithymocyte globulin persisting for 44 weeks, no post-transplant immunosuppression was given. No acute GVHD was detected by day 100, and limited skin GVHD was detected at 1 year. Engraftment was prompt, with a neutrophil count of 4500/mL on day 10 and platelet transfusion independence on day 13 after allogeneic HSCT. The patient was subsequently discharged from the ICU on day 123, with no radiological evidence of ongoing fungal infection ( Figure 1c ) and maintained on posaconazole until day 500.
BM examination performed on day 180 showed normal trilineage haematopoiesis, with complete morphological and cytogenetic remission. A large satellite on chromosome 21 (a normal variant) present on BM examination was consistent with successful donor chimerism. Now 4 years after transplant, the patient remains in remission, without GVHD, has made a full functional recovery and has excellent quality of life with a FACT-BMT 2 score of 145 (out of 148).
A recent case report of a patient with severe iatrogenic aplasia after chemotherapy for relapsed AML was successfully rescued with a conditioning regimen that utilised fludarabine alone and an unrelated HLA-identical allogeneic HSCT.
1 Although post-HSCT immune reconstitution is a complex process dependent on multiple variables (age of the recipient, conditioning regimen, presence of GVHD and ongoing immunosuppressive therapy), the neutrophil recovery in itself has the potential to control IFI. Given the disappointing results after granulocyte infusions in adults, the T-cell-depleted HSCT, purely aiming at neutrophil recovery, may be a viable treatment option in these critically unwell patients.
Aspergillosis has been the predominant IFI in severely immunocompromised patients since the early 1990s; however, there has been a recent rise in mucormycosis characterised by dissemination, aggressive angioinvasion and high mortality. 3 This has significant implications for the choice of antifungal agent for prophylaxis and treatment, particularly as voriconazole, currently the prophylatic agent of choice (in our institution) has no activity against mucorales. 3 Therapy involves an amphotericin B preparation and/or posaconazole, with radical surgical debridement. A recent retrospective study confirmed that pulmonary resection in high-risk immunocompromised patients with IFI can be carried out with low operative morbidity and mortality. 4 Medical therapy for IFI should comprise appropriate antifungal agents and immune reconstitution-neutrophils are known to be crucial for full recovery. Although usually considered high risk, allogeneic HSCT was considered here despite extensive IFI, as it was the only curative option for the underlying aplasia and hence led to neutrophil recovery. Thus, IFI should not necessarily preclude HSCT and may be life saving in carefully selected patients. 5, 6 To the best of our knowledge, this is the first case to undergo allogeneic HSCT in the setting of active IFI.
